Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with a 25.6% year-over-year earnings growth forecast and strong pipeline advancements, despite concerns over its premium valuation.

Square offers multiple tools to make life more simple for business owners. The company helps business owners send invoices, accept online payments and offer delivery, pickup and shipping options. It ...